Vyvgart Iv MG denied as non-formulary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for vyvgart iv mg are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Issues Non-Formulary Denials for Vyvgart IV in Myasthenia Gravis

Vyvgart (efgartigimod alfa, intravenous formulation) is a specialty biologic, and UnitedHealthcare formularies may exclude it, place it on a non-preferred tier, or require a formulary exception before coverage is extended. A non-formulary denial does not mean the therapy is medically inappropriate for the patient — it means the plan's standard benefit structure does not automatically cover it, and an exception must be justified.

## Why This Denial Is Appealable

Federal law and UHC plan documents require a formulary exception process. When the patient has a documented clinical need for Vyvgart IV specifically — including failure of, intolerance to, or contraindication against formulary alternatives — UHC must consider a formulary exception. An FDA approval for the precise diagnosis strengthens the exception request significantly. For generalized MG, which can be a life-threatening condition, the clinical stakes support an expedited review request.

## Federal Appeal Framework

• Formulary exception request: File this as the primary vehicle, with the prescriber's attestation that no formulary alternative is clinically appropriate for this patient. This is often faster than a formal appeal.
• Internal appeal: If the exception is denied, you retain full appeal rights under ACA §2719 and ERISA §503.
• External review: A final adverse determination on a formulary exception is subject to independent external review. Preserve this right by filing within the window on the denial letter (commonly around four months from the final internal denial).
• Expedited review: Request if gMG severity means standard timelines would cause serious harm, including any bulbar or respiratory symptoms.

## Documentation to Gather

1. gMG diagnosis and antibody status — neurology records confirming generalized MG and anti-AChR antibody-positive status consistent with the FDA-approved indication. 2. Formulary alternative evaluation — for each UHC formulary drug for gMG, document: whether it was tried (with dates and outcomes), why it is not appropriate, or why it is contraindicated for this patient. The prescriber must address each alternative specifically. 3. Disease severity documentation — functional status, validated severity measures used by the neurologist, and any prior acute events that establish urgency. 4. Prescriber formulary exception letter — explaining the clinical rationale for Vyvgart IV specifically and why no formulary alternative is adequate. 5. FDA prescribing information — demonstrating the approved indication matches the patient's diagnosis exactly. 6. UHC formulary and exception policy — identify the current formulary alternatives for gMG and the exception criteria, so every requirement is addressed.

## Criteria-Mapping Structure

Your exception request and appeal should include a dedicated section for each UHC formulary alternative: name, clinical reason it is inadequate or was tried and failed (with chart dates), and the specific documentation supporting that conclusion. Obtain the formulary and exception criteria from the current UHC plan documents — formularies change on a quarterly or annual cycle and prior-year versions may not reflect current requirements.